+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Gene Therapy Market - Global Forecast 2026-2032- Product Image
Cancer Gene Therapy Market - Global Forecast 2026-2032- Product Image
New

Cancer Gene Therapy Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 194 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010618
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The cancer gene therapy market is undergoing rapid transformation, driven by continual advances in vector engineering, cell therapy innovation, and evolving regulatory environments. Decision-makers now face both new opportunities and operational challenges as scientific breakthroughs enable more precise, personalized treatments.

Market Snapshot: Cancer Gene Therapy Market Size and Growth

The Cancer Gene Therapy Market grew from USD 3.30 billion in 2025 to USD 3.97 billion in 2026. It is expected to continue growing at a CAGR of 19.96%, reaching USD 11.81 billion by 2032. This robust growth highlights a sector shaped by scientific maturity, expanding clinical adoption, and increased investment in next-generation platforms.

Cancer Gene Therapy Market Scope & Segmentation

This report provides a comprehensive, segmentation-driven analysis of key trends, technologies, and market participants, offering actionable intelligence for senior leaders.

  • Vector Type: Nonviral vectors (lipid nanoparticles, physical methods, polymeric nanoparticles), viral vectors (adeno-associated, adenoviral, lentiviral, retroviral)
  • Therapy Type: Ex vivo and in vivo gene therapies
  • Indication: Hematological cancers (leukemia, lymphoma, myeloma), solid tumors (breast, colorectal, lung, prostate)
  • Development Stage: Preclinical, clinical trials (Phase I, II, III), and commercial stage programs
  • End User: Hospitals and clinics, oncology centers, research laboratories
  • Region: Americas, Europe, Middle East & Africa, Asia-Pacific

Key Takeaways for Senior Stakeholders

  • Scientific advances in gene therapy have expanded from single-gene interventions to encompass multi-modal strategies, including immune modulation and tumor microenvironment reprogramming.
  • Next-generation vector innovation and engineered cell therapies are enhancing precision and efficacy while mitigating safety concerns related to immune response and off-target effects.
  • Manufacturing modernization, featuring modular systems and digital process controls, allows for greater scale and operational flexibility, enhancing supply chain resilience for both autologous and allogeneic therapies.
  • Regulatory agencies are providing increasingly clear guidance, creating a more predictable pathway for approval and clinical deployment of new modalities.
  • Strategic partnerships, licensing, and co-development agreements are crucial for platform expansion, mitigating single-site risk, and accelerating late-stage development.

Cancer Gene Therapy Market: Tariff Impact and Supply Chain Strategy

Forthcoming United States tariff changes set for 2025 present material implications for the cancer gene therapy supply chain. Increased tariffs on imported raw materials, reagents, and specialized equipment may place margin pressure on organizations reliant on cross-border suppliers.

Key procurement adjustments include:

  • Supplier diversification and advanced contracting to stabilize material costs
  • Partnerships with contract manufacturers offering multi-jurisdictional capacity
  • Strategic localization of critical manufacturing steps to strengthen compliance and operational continuity

Role of Regional Factors

Regional dynamics affect regulatory approaches, manufacturing scale, clinical trial activity, and healthcare infrastructure. The Americas benefit from innovation hubs and rapid regulatory review, while Europe, Middle East & Africa require tailored entry and distribution strategies due to heterogeneous frameworks. Asia-Pacific’s growing biomanufacturing capacity and government support shape its expanding role in global supply chains. Adapting clinical deployment and supply strategies for local expectations is essential for successful commercialization.

Methodology & Data Sources

This cancer gene therapy market analysis utilizes a mixed-methods research framework, integrating primary interviews with industry experts, systematic reviews of peer-reviewed literature, and regulatory analysis. Triangulation across data sources ensures that insights reflect current industry practice and emerging scientific consensus.

Why This Report Matters

  • Enables data-driven decision-making by aligning scientific innovation with operational and regulatory realities
  • Supports senior leaders in identifying actionable strategies for technology adoption, supply chain resilience, and market access
  • Provides transparent, empirically derived insights that foster productive dialogue between clinical, commercial, and regulatory stakeholders

Conclusion

The cancer gene therapy market’s advancement relies on the alignment of scientific progress, operational maturity, and adaptive regulatory strategies. Stakeholders prioritizing platform innovation and end-to-end resilience will be best positioned to capture durable value as the sector evolves.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Cancer Gene Therapy Market, by Vector Type
8.1. Nonviral Vectors
8.1.1. Lipid Nanoparticles
8.1.2. Physical Methods
8.1.3. Polymeric Nanoparticles
8.2. Viral Vectors
8.2.1. Adeno-Associated
8.2.2. Adenoviral
8.2.3. Lentiviral
8.2.4. Retroviral
9. Cancer Gene Therapy Market, by Therapy Type
9.1. Ex Vivo
9.2. In Vivo
10. Cancer Gene Therapy Market, by Indication
10.1. Hematological Cancers
10.1.1. Leukemia
10.1.2. Lymphoma
10.1.3. Myeloma
10.2. Solid Tumors
10.2.1. Breast Cancer
10.2.2. Colorectal Cancer
10.2.3. Lung Cancer
10.2.4. Prostate Cancer
11. Cancer Gene Therapy Market, by Stage
11.1. Clinical Trials
11.1.1. Phase I
11.1.2. Phase II
11.1.3. Phase III
11.2. Commercial
11.3. Preclinical
12. Cancer Gene Therapy Market, by End User
12.1. Hospitals And Clinics
12.2. Oncology Centers
12.3. Research Laboratories
13. Cancer Gene Therapy Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Cancer Gene Therapy Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Cancer Gene Therapy Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Cancer Gene Therapy Market
17. China Cancer Gene Therapy Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Amgen Inc.
18.6. Autolus Therapeutics plc
18.7. Bayer AG
18.8. BioMarin Pharmaceutical Inc.
18.9. BioNTech SE
18.10. bluebird bio, Inc.
18.11. Bristol-Myers Squibb Company
18.12. Candel Therapeutics, Inc.
18.13. CARsgen Therapeutics Holdings Limited
18.14. Cellectis S.A.
18.15. CRISPR Therapeutics AG
18.16. F. Hoffmann-La Roche Ltd
18.17. Fate Therapeutics, Inc.
18.18. Iovance Biotherapeutics, Inc.
18.19. Janssen Biotech, Inc.
18.20. Kite Pharma, Inc.
18.21. Novartis AG
18.22. Precigen, Inc.
18.23. Sarepta Therapeutics, Inc.
18.24. Vertex Pharmaceuticals Incorporated
List of Figures
FIGURE 1. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CANCER GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CANCER GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENO-ASSOCIATED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LENTIVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. EUROPE CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 146. EUROPE CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 147. EUROPE CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 149. EUROPE CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 150. EUROPE CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 151. EUROPE CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 152. EUROPE CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 153. EUROPE CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 154. EUROPE CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. AFRICA CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 167. AFRICA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 168. AFRICA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 169. AFRICA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 170. AFRICA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 171. AFRICA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 172. AFRICA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 173. AFRICA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 174. AFRICA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 175. AFRICA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 176. AFRICA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 188. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 189. ASEAN CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. ASEAN CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 191. ASEAN CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 192. ASEAN CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 193. ASEAN CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 194. ASEAN CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 195. ASEAN CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 196. ASEAN CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 197. ASEAN CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 198. ASEAN CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 199. ASEAN CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. GCC CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 201. GCC CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 202. GCC CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 203. GCC CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 204. GCC CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 205. GCC CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 206. GCC CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 207. GCC CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 208. GCC CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 209. GCC CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 210. GCC CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. BRICS CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. BRICS CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 224. BRICS CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 225. BRICS CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 226. BRICS CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 227. BRICS CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 228. BRICS CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 229. BRICS CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 230. BRICS CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 231. BRICS CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 232. BRICS CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 233. G7 CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 234. G7 CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 235. G7 CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 236. G7 CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 237. G7 CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 238. G7 CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 239. G7 CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 240. G7 CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 241. G7 CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 242. G7 CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 243. G7 CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 244. NATO CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 245. NATO CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 246. NATO CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 247. NATO CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 248. NATO CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 249. NATO CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 250. NATO CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 251. NATO CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 252. NATO CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 253. NATO CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 254. NATO CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 255. GLOBAL CANCER GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 256. UNITED STATES CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 257. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 258. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 261. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 263. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 264. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 265. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 266. UNITED STATES CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 267. CHINA CANCER GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 268. CHINA CANCER GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
TABLE 269. CHINA CANCER GENE THERAPY MARKET SIZE, BY NONVIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 270. CHINA CANCER GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
TABLE 271. CHINA CANCER GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 272. CHINA CANCER GENE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 273. CHINA CANCER GENE THERAPY MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2032 (USD MILLION)
TABLE 274. CHINA CANCER GENE THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
TABLE 275. CHINA CANCER GENE THERAPY MARKET SIZE, BY STAGE, 2018-2032 (USD MILLION)
TABLE 276. CHINA CANCER GENE THERAPY MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
TABLE 277. CHINA CANCER GENE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Cancer Gene Therapy market report include:
  • Amgen Inc.
  • Autolus Therapeutics plc
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • BioNTech SE
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Candel Therapeutics, Inc.
  • CARsgen Therapeutics Holdings Limited
  • Cellectis S.A.
  • CRISPR Therapeutics AG
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics, Inc.
  • Iovance Biotherapeutics, Inc.
  • Janssen Biotech, Inc.
  • Kite Pharma, Inc.
  • Novartis AG
  • Precigen, Inc.
  • Sarepta Therapeutics, Inc.
  • Vertex Pharmaceuticals Incorporated

Table Information

Report AttributeDetails
No. of Pages194
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.97 Billion
Forecasted Market Value ( USD ) by 2032 $ 11.81 Billion
Compound Annual Growth Rate19.9%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Cell & Gene Therapy Clinical Trials Market - Global Forecast 2026-2032 - Product Image

Cell & Gene Therapy Clinical Trials Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Cell & Gene Therapy Services Market - Global Forecast 2026-2032 - Product Image

Cell & Gene Therapy Services Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Gene Therapy Market by Type (Gene Silencing), Vector (Viral (Retroviral, AAV), Non-Viral (Oligonucleotide)), Gene Type (Receptors, Cytokine), Therapeutic Area (Oncology, Neurology), Delivery Method (in-Vivo, Ex-Vivo), RoA (IV) - Global Forecast to 2032 - Product Image

Gene Therapy Market by Type (Gene Silencing), Vector (Viral (Retroviral, AAV), Non-Viral (Oligonucleotide)), Gene Type (Receptors, Cytokine), Therapeutic Area (Oncology, Neurology), Delivery Method (in-Vivo, Ex-Vivo), RoA (IV) - Global Forecast to 2032

  • Report
  • 434 Pages
  • Global
From
Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033 - Product Image

Gene Therapy Market Size, Share, Trends and Forecast by Gene Type, Vector Type, Delivery Method, Application, and Region, 2025-2033

  • Report
  • 140 Pages
  • Global
From
Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Large B-Cell Lymphoma, Multiple Myeloma), By Vector Type (Lentivirus, RetroVirus & Gamma RetroVirus, AAV), By Route Of Administration, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Large B-Cell Lymphoma, Multiple Myeloma), By Vector Type (Lentivirus, RetroVirus & Gamma RetroVirus, AAV), By Route Of Administration, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From

About the Cancer Gene Therapy Market

The Cancer Gene Therapy market is a subset of the larger Genomics market, which focuses on the study of genes and their functions. Cancer Gene Therapy is a form of treatment that uses genetic material to treat or prevent cancer. It involves introducing genetic material into cells to modify their behavior, such as to stop the growth of cancer cells or to make them more sensitive to chemotherapy. This type of therapy has the potential to be more effective and less toxic than traditional treatments. Cancer Gene Therapy is still in its early stages of development, but it has the potential to revolutionize cancer treatment. It is being studied in clinical trials and is expected to become more widely available in the future. Companies in the Cancer Gene Therapy market include Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, and Allergan. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.